ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,212.52
-0.44%
Dow Jones
38,297.32
0.49%
US Dollar vs MXN
16.9769
-0.19%
Brent Oil
81.315
-0.77%
Bitcoin
67,233.28
-1.65%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Stealth BioTherapeutics Corporation (MITO)

  7. Stealth BioTherapeutics Corporation (MITO) Noticias

MITO

Stealth BioTherapeutics (MITO)

Stealth BioTherapeutics Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MITO
FechaHoraFuenteTítuloSímboloCompañía
28/11/202217:41Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202215:23Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202215:16Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202215:10Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202215:08Edgar (US Regulatory)Amended Statement of Ownership: Private Transaction (sc 13e3/a)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202215:01PR Newswire (US)Stealth BioTherapeutics Corp Announces Completion of MergerNASDAQ:MITOStealth BioTherapeutics Corporation
01/11/202206:30PR Newswire (US)Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)NASDAQ:MITOStealth BioTherapeutics Corporation
07/10/202215:01PR Newswire (US)Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of ShareholdersNASDAQ:MITOStealth BioTherapeutics Corporation
30/09/202216:01TipRanksStealth Biotherapeutics announces resignation of CFO Robert WeiskopfNASDAQ:MITOStealth BioTherapeutics Corporation
30/09/202216:00PR Newswire (US)Stealth BioTherapeutics Announces Departure of Chief Financial OfficerNASDAQ:MITOStealth BioTherapeutics Corporation
23/09/202216:21Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:MITOStealth BioTherapeutics Corporation
15/09/202215:45PR Newswire (US)Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease EventsNASDAQ:MITOStealth BioTherapeutics Corporation
19/08/202208:50Edgar (US Regulatory)Statement of Ownership: Private Transaction (sc 13e3)NASDAQ:MITOStealth BioTherapeutics Corporation
01/08/202207:30PR Newswire (US)Stealth BioTherapeutics Corp Enters Definitive Agreement for Going Private TransactionNASDAQ:MITOStealth BioTherapeutics Corporation
11/07/202216:15PR Newswire (US)STEALTH BIOTHERAPEUTICS ANNOUNCES RECEIPT OF NON-COMPLIANCE NOTICE FROM NASDAQNASDAQ:MITOStealth BioTherapeutics Corporation
27/06/202209:25AllPennyStocks.comPremarket Indicating Higher Open For This BiotechNASDAQ:MITOStealth BioTherapeutics Corporation
27/06/202206:30PR Newswire (US)Stealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding ProposalNASDAQ:MITOStealth BioTherapeutics Corporation
16/06/202205:15TipRanksH.C. Wainwright Thinks Stealth Biotherapeutics’ Stock is Going to RecoverNASDAQ:MITOStealth BioTherapeutics Corporation
16/06/202205:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MITOStealth BioTherapeutics Corporation
14/06/202206:25PR Newswire (US)Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth SyndromeNASDAQ:MITOStealth BioTherapeutics Corporation
08/06/202209:15AllPennyStocks.comBiotech Company Catches Traders' Attention Second Time Within WeeksNASDAQ:MITOStealth BioTherapeutics Corporation
08/06/202206:20PR Newswire (US)Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration SymposiumNASDAQ:MITOStealth BioTherapeutics Corporation
03/06/202215:50Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:MITOStealth BioTherapeutics Corporation
31/05/202212:20AllPennyStocks.comBiotech Pops On News From The EMANASDAQ:MITOStealth BioTherapeutics Corporation
31/05/202206:25PR Newswire (US)Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Myopathic Mitochondrial DNA Depletion SyndromeNASDAQ:MITOStealth BioTherapeutics Corporation
23/05/202206:30PR Newswire (US)Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022NASDAQ:MITOStealth BioTherapeutics Corporation
23/05/202205:25TipRanksAnalysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Equillium (EQ) and Stealth Biotherapeutics (MITO)NASDAQ:MITOStealth BioTherapeutics Corporation
12/05/202206:30PR Newswire (US)Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular DystrophyNASDAQ:MITOStealth BioTherapeutics Corporation
06/05/202210:05TipRanksStealth Biotherapeutics (MITO) Gets a Buy Rating from Maxim GroupNASDAQ:MITOStealth BioTherapeutics Corporation
02/05/202206:30PR Newswire (US)STEALTH BIOTHERAPEUTICS ANNOUNCES DATA FROM RECLAIM-2 PHASE 2 TRIAL OF ELAMIPRETIDE IN GEOGRAPHIC ATROPHYNASDAQ:MITOStealth BioTherapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:MITO

Su Consulta Reciente

LSE
OQ12
Stand.chart.33u
NASDAQ
JWACU
Jupiter Wellness Acquisi...
NASDAQ
SGLBW
Sigma Labs
LBNK
AIFUSDT
AiForge Governance Token
TSXV
NID
COIN
RAYUST
Raydium
LBNK
UMIUSDT
UmiToken
LSE
43OH
Sg Issuer 24
BOV
PTBL3M
PORTOBELLO ON
NYSE
DCMT
DoubleLine ETF T
EU
BP23P
Banque Postalela null
NYSE
SKE
Skeena Resources
EU
ALGTR
Groupe Tera
ASX
ESGI
Vanguard Investments Aus...
AMEX
ADL
Amdl
NYSE
LEN.B
Lennar
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados